Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29794658 | 1.00 | IGF1R (0.80) | IGF1RNTRK1 | |
| SCHEMBL4155699 | 0.91 | NTRK1 (0.83) | IGF1RNTRK1 | |
| SCHEMBL4151532 | 0.91 | NTRK1 (0.83) | IGF1RNTRK1 | |
| SCHEMBL4164401 | 0.89 | IGF1R (1.00) | IGF1RNTRK1 | |
| SCHEMBL11344539 | 0.89 | IGF1R (1.00) | IGF1RNTRK1 | |
| SCHEMBL4152605 | 0.89 | IGF1R (1.00) | IGF1RNTRK1 | |
| SCHEMBL3338062 | 0.89 | NTRK1 (0.79) | IGF1RNTRK1 | |
| SCHEMBL29794741 | 0.89 | NTRK1 (0.79) | IGF1RNTRK1 | |
| SCHEMBL4072338 | 0.89 | NTRK1 (0.79) | IGF1RNTRK1 | |
| SCHEMBL4064474 | 0.89 | NTRK1 (0.79) | IGF1RNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158756-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-05-16 | — | — | US | disclosed |
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2021072238-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-04-15 | — | — | WO | disclosed |
| US-10907215-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10724102-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10655186-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| EP-3368039-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | The Regents of The University of Colorado, A Body Corporate (US) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017075107-A9 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-08-02 | — | — | WO | disclosed |
| US-20180142306-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA INC. | 2018-05-24 | — | — | US | disclosed |
| US-20180119228-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20170260589-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2017-09-14 | — | — | US | disclosed |
| WO-2017075107-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NANDA NISHA (US) | 2017-05-04 | — | — | WO | disclosed |
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| EP-1877057-A1 | USE OF PYRAZOLYL-PYRIMIDINE DERIVATIVES IN THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006115452-A1 | USE OF PYRAZOLYL-PYRIMIDINE DERIVATIVES IN THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119228-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | IGF1R 417/4885NTRK1 2/4885 |
| US-10907215-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | IGF1R 417/4885NTRK1 2/4885 |
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | IGF1R 404/4885NTRK1 2/4885 |
| US-20180142306-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | IGF1R 417/4885NTRK1 2/4885 |
| US-10655186-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | IGF1R 404/4885NTRK1 2/4885 |
| US-20170260589-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | IGF1R 417/4885NTRK1 2/4885 |
| US-10724102-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | IGF1R 404/4885NTRK1 2/4885 |
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | P2RX3, DPYD, TYMP | IGF1R 4775/4885NTRK1 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.